Patents Represented by Attorney, Agent or Law Firm Elizabeth J. Hecht
-
Patent number: 7736639Abstract: Methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides and substitution mutants thereof that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein are disclosed.Type: GrantFiled: December 21, 2007Date of Patent: June 15, 2010Assignee: GlaxoSmithKline LLCInventors: Narendra Bam, Jacob Bongers, Robert B. Kirkpatrick, Cheryl A. Janson, Zdenka Jonak, Xianyang Qiu, Ping Yeh, Kyung Johanson
-
Patent number: 7655425Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.Type: GrantFiled: September 3, 2004Date of Patent: February 2, 2010Assignee: Glaxo Group LimitedInventors: Timothy N. C. Wells, Christine A. Power
-
Patent number: 7595039Abstract: The present invention relates generally to the use of human IL-18, also known as interferon-?-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury.Type: GrantFiled: August 19, 2005Date of Patent: September 29, 2009Assignee: SmithKline Beecham CorporationInventors: Kimberly A. Dede, Judithann M. Lee
-
Patent number: 7442526Abstract: The present invention provides a method for producing physiologically active human Interleukin-18 (“IL-18”).Type: GrantFiled: April 11, 2006Date of Patent: October 28, 2008Assignee: SmithKline Beecham CorporationInventors: Kyung O. Johanson, Robert B. Kirkpatrick, Allan R. Shatzman, Yen Sen Ho, Patrick McDevitt
-
Patent number: 7399593Abstract: The invention provides an isolated protein which is a member of the TNF ligand superfamily and comprising: i) a polypeptide having the amino acid sequence of FIG. (1) or ii) a variant of the polypeptide of i).Type: GrantFiled: October 5, 1999Date of Patent: July 15, 2008Assignee: SmithKline Beecham CorporationInventors: Stuart Neville Farrow, Allard Kaptein, Jeremy David Alisdair Kitson, Alison Janet Winder
-
Patent number: 7316813Abstract: An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may comprise a micelle modifying excipient, for example ?-tocopherol or a derivative thereof in a sufficient amount to stabilize the haemagglutinin.Type: GrantFiled: May 29, 2002Date of Patent: January 8, 2008Assignee: Saechsisches Serumwerk Dresden Branch of SmithKline Beecham Pharma GmbH & Co KGInventor: Uwe Eichhorn
-
Patent number: 7311902Abstract: Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.Type: GrantFiled: April 14, 2004Date of Patent: December 25, 2007Assignee: SmithKline Beecham CorporationInventors: Narendra Bam, Jacob Bongers, Robert B. Kirkpatrick, Cheryl A. Janson, Zdenka Jonak, Xianyang Qiu, Ping Yeh, Kyung Johanson
-
Patent number: 7285280Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.Type: GrantFiled: August 15, 2000Date of Patent: October 23, 2007Assignee: SmithKline Beecham Biologicals s.a.Inventors: Brigitte Desiree Alberte Colau, Francoise Denamur, Isabelle Knott, Annick Poliszczak, Vincent Vande Velde
-
Patent number: 7253260Abstract: A novel human IL-18 native crystalline structure is identified.Type: GrantFiled: April 16, 2003Date of Patent: August 7, 2007Assignee: SmithKline Beecham CorporationInventors: Cheryl A. Janson, Nestor O. Concha
-
Patent number: 7238349Abstract: The invention provides a monovalent influenza vaccine comprising a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, in combination with an aluminium adjuvant. The invention also provides vaccine kits comprising a combination of a parenteral and a mucosal influenza vaccine, wherein the combined dose of antigen is no more than the conventional antigen dose. Also provided are methods for preparing the vaccines.Type: GrantFiled: September 27, 2000Date of Patent: July 3, 2007Assignees: SmithKline Beecham Biologicals, s.a., Saechsisches Serumwerk DresdenInventors: Erik D'Hondt, Norbert Hehme
-
Patent number: 7186528Abstract: A method for producing a physiologically active polypeptide, comprising contacting a precursor polypeptide with an activating enzyme, or co-expressing the polypeptide with an activating protease.Type: GrantFiled: June 11, 2001Date of Patent: March 6, 2007Assignee: SmithKline Beecham CorporationInventors: Robert B. Kirkpatrick, Allan R. Shatzman
-
Patent number: 7008623Abstract: The invention relates to antibodies which bind to the CD23 (FC?RII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FC?RII) type II molecule characterized by an affinity constant equal to or greater than 1×109 Ka Mol?1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.Type: GrantFiled: May 7, 1999Date of Patent: March 7, 2006Assignee: Glaxo Wellcome Inc.Inventors: Jean-Yves Marcel Paul Bonnefoy, James Scott Crowe, Jonathan Henry Ellis, Nicholas Timothy Rapson, Jean Shearin
-
Patent number: 6881827Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.Type: GrantFiled: August 9, 2002Date of Patent: April 19, 2005Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Nabil Elshourbagy, Usman Shabon, Robert S. Ames, Henry S. Sarau, Lisa Vawter, David Michalovich
-
Patent number: 6750026Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.Type: GrantFiled: December 15, 2000Date of Patent: June 15, 2004Assignees: SmithKline Beecham Corporation, Board of Regents The University of Texas SystemInventors: Derk J. Bergsma, David P. Brooks, Miklos Gellai, Shelagh Wilson, Masashi Yanagisawa
-
Patent number: 6706487Abstract: Chimeric, humanized and other IL-18 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: GrantFiled: August 31, 2001Date of Patent: March 16, 2004Assignee: SmithKline Beecham CorporationInventors: Sherin S. Abdel-Meguid, Yen Sen Ho, Stephen D. Holmes, Alexander H. Taylor
-
Patent number: 6664229Abstract: Polypeptides of HFGAN72 receptor ligands and polynucleotides encoding the polypeptides are provided. Methods of using these polypeptides to diagnose or treat diseases relating to the under- or over-expression of HFGAN72 receptor ligands are also provided. In addition, methods of identifying agonists or antagonists of the interaction of HFGAN72 receptor ligands with the HFGAN72 receptor are provided. Methods of treatment by administering the identified agonists or antagonists to patients in need thereof are further disclosed.Type: GrantFiled: December 15, 1998Date of Patent: December 16, 2003Assignee: SmithKline Beecham p.l.c.Inventors: James Joseph Hagan, Jonathan Alexander Terrett, Neil Upton, David Piper, Martin Ian Smith, Guy Anthony Kennett, Saraswati R. Patel
-
Patent number: 6582689Abstract: The present invention relates generally to compositions comprising potentiators, such as IL-18, also known as interferon-&ggr;-inducing factor (IGIF), in combination with a chemotherapeutic agent, processes for making such compositions, the use of such compositions for the prevention and/or treatment of cancer, and the use of such compositions to inhibit the growth of tumors or cancerous cells in mammals.Type: GrantFiled: November 17, 2000Date of Patent: June 24, 2003Assignee: Smithkline Beecham CorporationInventor: Randall K. Johnson
-
Patent number: 6573074Abstract: Improved purification methods for ansamitocins are disclosed.Type: GrantFiled: April 9, 2001Date of Patent: June 3, 2003Assignee: SmithKline Beecham plcInventors: Mark Fulston, Anna L. Stefanska, Jan E. Thirkettle
-
Patent number: 6506878Abstract: HMTMF81 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HMTMF81 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.Type: GrantFiled: June 5, 2000Date of Patent: January 14, 2003Assignee: Smithkline Beecham CorporationInventors: Catherine E. Ellis, Wendy Halsey, Ganesh M. Sathe, Robert S. Ames, James J. Foley, Henry M. Sarau, Jon Chambers
-
Patent number: 6461836Abstract: AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.Type: GrantFiled: April 10, 2000Date of Patent: October 8, 2002Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.Inventors: Nabil Elshourbagy, Usman Shabon, Robert S. Ames, Henry S. Sarau, Lisa Vawter, David Michalovich